Strengthening Our Impact with Growth and Expansion of Our Capabilities
At Veristat, we champion innovation through the solutions we provide our clients across clinical trials and on specialized projects, supporting the success of therapies designed to extend, save and enrich lives. Over the years, we have strategically invested in organizations, people and resources to help our clients solve their most complex challenges.
With our bold scientific strategies and a team unafraid of big thinking, we are passionate about helping you get your therapy to market– and keep it there – quickly, safely and cost-effectively.
HISTORY AND TIMELINE OF VERISTAT'S GROWTH
Veristat was founded by John and Barbara Balser, marking the start of a Clinical Research Organization (CRO) dedicated to solving the most difficult scientific and clinical challenges.
Veristat becomes a registered CDISC solutions provider, integral to our offering to ensure timely and compliant FDA submissions and reviews.
Veristat adds Clinical Operations Services, expanding our ability to conduct clinical trials with the highest levels of scientific excellence, efficiency and results.
Patrick Flanagan joins as CEO to lead the company’s business strategy, organizational management and financial performance.
Veristat expands into Europe with the acquisition of Spero Oncology and launches our Strategic Consulting Group.
Clinical Operations Services are strengthened with the acquisition of Topstone Clinical Research.
Regulatory Services are established, foundational to Veristat’s core service offering.
Operations expand into Asia with the opening of Veristat’s Taipei office.
The acquisition of Catalyst strengthens North American capabilities in Regulatory Affairs.
Veristat’s acquisition of TCTC brings substantive capabilities and talent in Advanced Therapy solutions, furthering geographic reach into the UK and EU regions.
The acquisition of Certus PV advances Veristat’s commitment to patient safety by adding post-market pharmacovigilance services.
Enhances patient-centricity offering by launching a flexible virtual clinical trial solution.
Veristat’s impact in Biometrics and European Regulatory is enhanced with the acquisitions of SQN Clinical and DDR.
European footprint expands with the opening of our Barcelona office.
The acquisition of SFL adds commercialization capabilities, expands our EU footprint and diversifies our client base.
Launches Strategic Resourcing/FSP solutions to build greater flexibility for sponsors.
Integrates Decentralized Clinical Trial (DCT) solutions into our clinical development full-service offerings